Over the past four years, INCATE has been supporting early-stage ventures working on innovations to address the challenge of antimicrobial resistance (AMR). INCATE's portfolio spans a wide range of innovative solutions, and the progress of [...]
More news
Unison Medicines is delighted to announce an oversubscribed first close of $500k of financing from [...]
We are happy to announce a new partnership with Granzer Regulatory Consulting & Services GmbH [...]
From bone flutes to synths, music has always been more than noise — it’s how [...]
The INCATE Selection Committee has chosen four new ventures for Stage I support. Meet the [...]
Did you know phages helped stop a cholera outbreak in Stalingrad during WWII? While antibiotics [...]
In 2025, it is possible — and increasingly common — to treat cancer but lose [...]
At INCATE, we are committed to providing support to early-stage innovators working on antimicrobial resistance [...]
On February 7, 2025, Swiss biopharmaceutical innovator BioVersys made its debut on the SIX Swiss [...]
